Yunkang Group Ltd

Yunkang Group Ltd maintains a strong liquidity position, with cash and equivalents amounting to CNY 1.52 billion, significantly exceeding its total liabilities of CNY 1.58 billion. The company's liquidity FPT (free cash flow to total liabilities) is robust, indicating a low liquidity risk. The current ratio of 1.59 further supports the company's ability to meet short-term obligations. Profitability metrics show a mixed picture. The company's return on equity (ROE) is 0.25%, and return on assets (ROA) is 0.11%, both below the industry median for healthcare providers. The net income of CNY 2.92 million is relatively low compared to revenue of CNY 601.39 million, suggesting margin compression or high operating costs. The gross profit margin of 30.4% is in line with industry norms, but the operating margin of 5.5% is below the median for the sector. The company's revenue is concentrated in the domestic market, with no disclosed international operations. The three business segments—diagnostic outsourcing, diagnostic testing for medical institution alliances, and diagnostic testing for non-medical institutions—each contribute to the revenue, but the financial breakdown by segment is not provided in the input data. This lack of transparency limits the ability to assess the performance of individual business lines. Looking ahead, the company's revenue is expected to grow, though the exact rate is not specified. The current FY outlook is positive, with a projected increase in revenue. The next FY outlook is also favorable, with a continuation of the growth trend. The company's operating income has shown a decline in recent periods, but the overall revenue trajectory remains upward. Risk factors include a low liquidity risk and a low dilution risk, as no immediate filing-based liquidity or dilution flags were detected. The company's debt-to-equity ratio of 0.6 is relatively low, indicating a conservative capital structure. The absence of dilution potential and the low risk of equity dilution suggest that the company is not under pressure to raise additional capital through equity issuance. Recent events include the company's continued focus on expanding its diagnostic testing services and strengthening its partnerships with hospitals and medical institutions. No significant regulatory or legal issues were disclosed in the input data. The company's recent financial performance and strategic initiatives suggest a stable and growing business.